Showing 881-890 of 20379 results for "".
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
https://reachmd.com/programs/cme/the-4-hit-hypothesis-foundations-of-igan-pathogenesis/51035/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
https://reachmd.com/programs/cme/targeting-lower-proteinuria-levels-shifting-the-goalpost-in-igan/54686/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Does an IV Hydration Therapy Practice Need a Medical Director?
https://reachmd.com/ma-issues-index/2022-nov-dec/does-an-iv-hydration-therapy-practice-need-a-medical-director/35231/It’s important to understand requirements in your state.Personalizing PNH Care: Exploring the Role of Iptacopan in Clinical Practice
https://reachmd.com/programs/medical-industry-feature/personalizing-pnh-care-iptacopan/35650/While patients with paroxysmal nocturnal hemoglobinuria (PNH) share the same diagnosis, they show a range of hemoglobin levels and symptoms.1,2 C5 inhibitors have reduced mortality and morbidity in patients with PNH, but FABHALTA® (iptacopan) may offer another treatment option that can match individNew Treatments in IBD – Professional Webinar Series
https://reachmd.com/programs/cme/new-treatments-in-ibd-professional-webinar-series/15694/Join us for this module of the IBD Pro Webinar Series presentation titled “New Treatments in IBD”. The talk will include new medications, positioning, real world evidence, and the Foundation's EMR IBD Education Tool. The 45 minute presentation will be followed by a 15 minute question and answer sIFPA World PsO and PsA Conference
https://reachmd.com/programs/practical-dermatology-focus-psoriasis/ifpa-world-pso-and-psa-conference/29084/The International Federation of Psoriasis Associations (IFPA) hosted its 7th World Psoriasis and Psoriatic Arthritis Conference in late June in Stockholm, Sweden. Topics covered included genetics/immunology, prevention of psoriatic arthritis, understanding pain and itch, treatment advances in topicaEarly Onset of Response to Zasocitinib (TAK-279), a Highly Selective and Potent TYK2 Inhibitor, Is Correlated With Modulation of TYK2 Signaling and Disease Pathway Biomarkers in Patients With Moderate-to-Severe Plaque Psoriasis
https://reachmd.com/clinical-practice/dermatology/early-onset-of-response-to-zasocitinib-tak-279-a-highly-selective-and-potent-tyk2-inhibitor-is-correlated-with-modulation-of-tyk2-signaling-and-disease-pathway-biomarkers-in-patients-with-moderate-to-severe-plaque-psoriasis/50977/Review phase 2b trial data on zasocitinib in patients with moderate-to-severe plaque psoriasis.Is Gastric Bypass or Lap Band Right for Your Patients?
https://reachmd.com/programs/gi-insights/is-gastric-bypass-or-lap-band-right-for-your-patients/4320/What are the advantages to each of the two main types of obesity surgeries— gastric bypass and lap band surgery? How do the recovery times, efficacy and potential complications compare? Host Dr. Mark DeLegge welcomes Dr. T. Karl Byrne, professor of surgery and medical director of the Bariatric SurgeDecoding Proteinuria: A Window into Kidney Health in IgAN
https://reachmd.com/programs/clinicians-roundtable/decoding-proteinuria-a-window-into-kidney-health-in-igan/27029/Explore how protein levels in urine can help predict long-term kidney health in patients with IgAN.Women in Aesthetics: Isabelle Raymond, PhD
https://reachmd.com/ma-issues-index/september-october-2025/women-in-aesthetics-isabelle-raymond-phd/39727/Get to know Isabelle Raymond, PhD, SVP Global Medical and Clinical Affairs with Nutrafol